Vertex acquires Crinetics Pharmaceuticals for $10 billion
Vertex Pharmaceuticals will spend $10 billion to acquire Crinetics Pharmaceuticals and its rare endocrine disorder treatment, marking continued biotech consolid
STAT · +14 outlets
FDA expands Casgevy (CRISPR gene therapy) approval to children as young as 2
Vertex's Casgevy becomes available to younger pediatric patients with sickle cell disease and transfusion-dependent beta-thalassemia, broadening access to the f
BioPharm International · +14 outlets
Novartis acquires Myricx Bio for $1.1 billion to expand antibody-drug conjugates
Novartis is expanding its antibody-drug conjugate development pipeline through the acquisition of Myricx Bio, marking another significant industry consolidation
STAT · +14 outlets
Opus Genetics aligns with FDA on Phase 3 trial design for LCA5 inherited retinal disease
Gene therapy developer Opus Genetics receives FDA alignment on its Phase 3 registrational trial for OPGx-LCA5, moving forward with treatment for LCA5-associated
Investing.com · +5 outlets
SMA gene therapy approved in Europe for treatment of all ages
A spinal muscular atrophy gene therapy gains European regulatory approval without age restrictions, expanding treatment options for the rare genetic disorder.
SMA News Today · +14 outlets
Rocket Pharmaceuticals FDA approves first gene therapy for rare childhood immune disease
Rocket Pharmaceuticals receives FDA approval for its gene therapy treating a rare pediatric immunodeficiency disorder.
Stocktwits · +14 outlets
Sarepta announces FDA acceptance of supplemental NDAs for dystrophy treatments
Sarepta Therapeutics receives FDA acceptance of supplemental new drug applications for AMONDYS 45 and VYONDYS 53, marking progress for its muscular dystrophy pi
Sarepta Therapeutics · +3 outlets
Cancer and immune therapies dominate venture capital funding in 2026
Oncology and immunotherapy companies represent more than 40 percent of biotech VC funding and deal volume in the first half of 2026.
BioPharma Dive · +12 outlets
Scribe Therapeutics, gene-editing company with major pharma partnerships, plans IPO
The California-based gene-editing company with collaborations from Biogen, Sanofi, and Eli Lilly could become the 14th biotech IPO in 2026.
BioPharma Dive · +6 outlets
FDA clears first human trial of age-reversal eye therapy
Regulatory approval is granted for the first human trial of an experimental therapy designed to reverse aging in eye tissue.
MSN · +14 outlets
FDA clears transplant therapy reducing chronic GVHD from 44 percent to 13 percent
A transplant-related therapy gains FDA clearance with clinical data showing substantial reduction in chronic graft-versus-host disease.
The Eastern Herald · +1 outlets
GLP-1 telehealth prescriptions often lack adequate clinical oversight
A secret-shopper study reveals that GLP-1 prescriptions from telehealth platforms frequently bypass appropriate clinical evaluation.
STAT · +14 outlets
Celltrion files amendment for Phase 3 trial of Keytruda biosimilar CT-P51 in US
South Korean biopharmaceutical Celltrion advances its biosimilar development program with an amended Phase 3 trial filing for the Keytruda competitor.
Seoul Economic Daily
Pharvaris wins FDA review for oral hereditary angioedema attack treatment
FDA accepts Pharvaris' application for an oral treatment of hereditary angioedema attacks, potentially offering a new dosing option for the rare genetic disorde
Stock Titan · +4 outlets
GOP lawmakers push FDA to ensure clinical trial diversity
Republican lawmakers advocate for FDA clinical trial diversity protections, framing the issue as scientific necessity rather than policy initiative.
STAT · +3 outlets
Anthropic CEO discusses AI impact on drug discovery and biotech
Anthropic leadership shares perspectives on how artificial intelligence is reshaping pharmaceutical development and biotech research.
STAT · +3 outlets
Vera Therapeutics' kidney disease drug shows patient benefit ahead of FDA review
Vera Therapeutics reports patient-level outcomes for its renal disease treatment as the company approaches FDA evaluation.
The Business Journals · +13 outlets
FDA clears Vivos to test RadioGel in first US cancer patients
Vivos receives FDA clearance to initiate clinical testing of RadioGel, a radiotherapy enhancement technology in US cancer patients.
Stock Titan · +1 outlets